| |
| |
 |
| |
| By Angus Chen MD Anderson Cancer Center The shortage of CAR-T therapy for multiple myeloma is creating a gut-wrenching dilemma for clinicians — deciding who gets the chance to live. Read More |
| By Matthew Herper Courtesy Memorial Sloan Kettering A trial of GSK's cancer drug Jemperli in patients with a rare genetic signature in their tumors delivered impressive results. Read More |
| By Adam Feuerstein Courtesy ASCO/Scott Morgan The off-the-shelf therapy made from a special type of T cell induced complete remissions in patients with advanced B-cell lymphomas. Read More |
| Sponsor content by Dana-Farber Cancer Institute Newly identified regulator in prostate cancer cells could serve as drug target for advanced tumors Aiming to discover new targets for blocking androgen receptor activity, a Dana-Farber-led team has identified a critical regulator of AR signaling that prostate cancer cells depend on, according to their publication in Cell Reports. In the laboratory, the team showed that inhibiting this regulator — a protein called PRMT1 — reduced androgen receptor activity and blunted its effect on cancer genes that whose expression was elevated by the AR receptor. Read more. |
| By Adam Feuerstein The outcome of the Cel-Sci Phase 3 study of the immunotherapy Multikine in patients with head and neck cancer is clear. Read More |
| By Matthew Herper AP Daiichi Sankyo and AstraZeneca, said that, if regulators clear the way, the number of patients eligible to receive the drug could be tripled. Read More |
| By Angus Chen Angus Chen/STAT Researchers said the results should force clinicians to see the racial biases that health care has both on a structural and a personal level. Read More |
| By Adam Feuerstein FDA Pazdur addressed a wide range of subjects at a STAT event during the annual meeting of the American Society of Clinical Oncology. Read More |
| By Ed Silverman FABRICE COFFRINI/AFP/Getty Images Documents reviewed by STAT illustrate issues at a Novartis facility where production of a cancer treatment was halted this month. Read More |
| By Adam Feuerstein SEBASTIEN BOZON/AFP via Getty Images In the study called SKYSCRAPER-02, tiragolumab combined with a two-drug standard of care performed worse than the control arm. Read More |
| By Ed Silverman Melissa Rendler-Garcia of UICC spoke with STAT about a new effort to license cancer drugs in low-income countries. Read More |
| By Matthew Herper GUILLERMO ARIAS/AFP via Getty Images The lead author of the study described the results as "striking," though it relied on observational data and not a randomized clinical trial. Read More |
| By Angus Chen New targets, faster manufacturing times, and dual strategies against a cancer that does not currently have a cure. Read More |
| By Matthew Herper Courtesy Bristol Myers Squibb The acquisition gives Bristol a biotech that is developing medicines that fight cancer by targeting specific mutations. Read More |
No comments